培土生金化瘀中药对肺间质纤维化大鼠干预作用的实验研究
|
摘要
肺间质纤维化是一组以肺间质弥漫性渗出、浸润和纤维化为主要病变的疾病,它是许多肺间质疾病的共同结局,病程一般呈进行性发展。其病理特点为慢性炎症反应导致肺泡上皮持续损伤、成纤维细胞过度增殖和细胞外基质过度沉积。由于其发病机制目前尚未完全明确,因此临床尚缺乏特异的治疗药物[1]。传统治疗以糖皮质激素和免疫抑制剂为主,主要是通过减轻炎症反应来延缓肺纤维化的进程[2],但临床诊断的肺纤维化患者,绝大多数纤维化已经形成,并不断进展[3],加之激素疗效尚不理想,长期使用会产生明显不良反应[2],因此开发疗效好、安全性高的药物已成为当务之急。
中医理论多将肺纤维化归为“咳嗽”“喘证”、“肺痹”等范畴,认为肺纤维化的病位在肺,而与多脏器有关,病机多为正虚邪实。本实验结合古今文献的研究,根据五行相生等的中医基础理论及长期的临床观察,认为该病病位虽然在肺,但与脾密切相关,病机以虚、瘀为关键,提出了肺纤维化“脾虚血瘀”的中医病机假说,由此针对肺纤维化主要病理变化,采用培土生金,活血化瘀的基本治法,拟定培土生金化瘀中药复方加减变化治疗该病,在临床实践中取得了较为满意的效果。为了进一步探讨该复方治疗肺纤维化的作用机理,我们采用该药复方治疗肺间质纤维化大鼠,选择相关分子生物学指标,通过现代先进的实验技术,从不同层面、不同水平动态观察中药复方对实验性肺纤维化的影响,进而探讨其治疗肺纤维化的机理,为肺纤维化的临床治疗提供理论依据。
本实验采用博莱霉素复制大鼠肺纤维化模型,分别在7天、14天、28天三个时间点,研究培土生金化瘀中药复方对肺纤维化大鼠的干预作用,从分子生物学、免疫学、病理学等不同层面来探讨该中药复方的作用机制。实验研究共分为四部分:
1培土生金化瘀中药对博莱霉素所致大鼠肺纤维化的肺组织形态及肺系数的影响
通过对模型动物一般状况的观察(如体重、活动、饮食、及呼吸等)及对肺重、肺系数、病理形态学的研究(HE染色、MASSON染色),通过进行数据统计来比较培土生金化瘀中药的作用效果,以观察培土生金化瘀中药复方对肺间质纤维化大鼠的影响,。
结果显示:除了正常组外,其余各组大鼠均有不同程度的活动减少、体重下降、饮食减少以及肺系数的增加;肺组织HE染色和MASSON染色均可见程度不同的肺泡炎和细胞外基质沉积。经培土生金化瘀中药复方治疗后大鼠一般状态有所好转;肺系数有所减少;病理形态学显示肺泡炎及肺纤维化均有不同程度的改善。
结论:(1)博莱霉素诱导大鼠肺纤维化模型成功。
(2)培土生金化瘀中药复方能在一定程度上改善肺间质纤维化大鼠的肺泡炎及肺纤维化。
2培土生金化瘀中药对博莱霉素所致大鼠肺纤维化羟脯氨酸含量影响的机制研究
通过对肺纤维化模型大鼠羟脯氨酸含量影响的实验研究,探讨在肺间质纤维化形成过程中羟脯氨酸含量的变化情况。羟脯氨酸是机体胶原蛋白的主要成分之一,在弹性蛋白中含量极少,而在其它蛋白则不存在[4]。因此,羟脯氨酸为胶原纤维所特有,以此作为肺纤维化的指标,可以判断肺纤维化的程度。
结果显示:除正常组外其余各组大鼠肺组织胶原沉积明显,数据显示羟脯氨酸含量有不同程度的增加,且纤维化程度随时间的推移而持续加重。经培土生金化瘀中药复方治疗后羟脯氨酸含量有所下降,从而间接地降低肺组织中胶原的含量,起到了减轻肺纤维化的作用。
结论:培土生金化瘀中药复方可减少肺间质纤维化大鼠的羟脯氨酸含量,从而使纤维化大鼠的纤维化程度有所改善。
3培土生金化瘀中药对肺间质纤维化大鼠肺组织中TGF-β1及MCP-1蛋白表达影响的机制研究
通过免疫组织化学染色的方法,结合图像半定量分析技术,研究TGF-β1及MCP-1不同时期的蛋白表达,从免疫组化方面进一步探讨了培土生金化瘀中药对肺纤维化的作用机制。
结果显示:在肺纤维化发展的各个时间点,TGF-β1及MCP-1蛋白在肺组织中的表达均较正常组明显升高。经培土生金化瘀中药复方治疗后,TGF-β1及MCP-1蛋白表达有不同程度的降低,提示培土生金化瘀中药复方可能通过抑制TGF-β1及MCP-1在肺组织中的异常高表达,从而使肺纤维化程度有所减轻。
结论:培土生金化瘀中药复方可调节TGF-β1及MCP-1蛋白的表达,从免疫组化方面使肺纤维化的程度有所减轻。
4培土生金化瘀中药对肺间质纤维化肺组织TGF-β1mRNA基因表达影响的机制研究
本实验采用RT-PCR的方法,结合图像分析技术,比较各组肺组织在不同时间点上TGF-β1mRNA的基因表达,从分子生物学方面进一步探讨了培土生金化瘀中药的作用机制。
结果显示:在肺纤维化发展的各个时间点,TGF-β1mRNA在肺组织中均有表达,且强度与正常组比较有显著性差异。经培土生金化瘀中药复方治疗后,TGF-β1mRNA在肺组织中的表达有不同程度的下调,提示培土生金化瘀中药复方可抑制纤维化大鼠的TGF-β1mRNA基因表达,从而改善纤维化,达到预防与治疗的目的。
结论:培土生金化瘀中药复方可下调TGF-β1mRNA在肺组织中的基因表达,从而表明该中药复方可在分子生物学水平减轻肺纤维化的程度。
综上所述,本课题采用博莱霉素复制肺纤维化动物模型,应用培土生金化瘀中药复方对肺纤维化大鼠进行干预治疗,从不同层面、不同水平研究培土生金化瘀中药复方对肺纤维化大鼠的作用机制。结果表明,该中药复方能有效的改善肺纤维化的病理状态、降低羟脯氨酸含量、抑制了TGF-β1mRNA、TGF-β1及MCP-1蛋白在肺内的高表达,从而减轻了肺纤维化大鼠的肺泡炎及肺纤维化程度,阻断了纤维化的病理进程,为今后肺纤维化的临床治疗提供了更为坚实的理论依据。
Pulmonary interstitial fibrosis (PF) is a kind of disease characterized by diffusion, infiltration and fibrosis as a common outcome of many interstitial lung diseases. Constantly, the course of PF progressively develops. Its pathological features are the chronic inflammation leading to persistent injury of alveolar cell, over reproduction of lung fibroblast (FB) and excess deposition of extracellular matrix (ECM). It′s well known, the injury of tissues is usually accompanied by inflammation and repairing course. If the scope of injury is small, tissues can recover to normal structure and function, such as the infection reducing by most of bacteria and virus. Otherwise when the range is relatively big or recurrence, the frequent repairing will lead to fibrosis or scar formation, which will influence flexibility and respiratory function and induce the patient died of heart and lung failure as well as hypoxemia. As result of its pathogenesis is not thoroughly clear so far, there is no specific medicine in clinic. The traditional medicine is mainly glucocorticoid and immunosuppressant, delaying the course of PF through relieving inflammation. But to the patient diagnosed as PF in clinic, not only fibrosis has been developing and the disease condition had been developing continuously, but also the curative effect is still dissatisfactory and obvious adverse reactions were induced after long application. Therefore at present, the urgent question is to develop the better effect and high security medicine for PF.
PF is mostly divided into the category of“Consumptive Lung Disease”“Bi syndrome of the lung”in TCM, believed that the location of PF is in lung, also relating to multiple viscera, and its pathogenesis due mostly to deficient vitality and excessive evil. Through combining with the study on the ancient and modern literature and the long clinical observation, we considered that this disease is belonged to the category of“Consumptive Lung Disease”, and the ill location lies in lung, but closely connective with spleen, and the key of pathogenesis is deficiency and stasis, so we put forward the hypothesis of deficiency of spleen and blood stasis. Furthermore combining with the theory of TCM, we also believes that invigorating spleen and lung, promoting blood and stasis-resolving is the basically big method, and applies the modification of the herbal compound of strengthening earth to support metal and stasis-resolving in treating PF, and has achieved the satisfactory effects in clinic. In order to further explore the effect of the herbal compound on PF, we apply the compound to treat PF rats, choose relative molecular biological markers, and use advanced experimental technique, observing the effect of the herbal compound on PF rats from different levels and angels, which provide theory basis for treating PF in clinic.
In this experiment, we apply BLM to induce the PF model on rats, studying the effect of“strengthening earth to support metal and stasis-resolving compound”on PF rats, at the time of 7d,14d and 28d, exploring the mechanism of the herb from the different levels and angels such as molecular biology, immunity and pathology etc,so as to find the more effect medicines for the clinic. The experimental research consists of four parts as following:
1 The effects of“strengthening earth to support metal and stasis-resolving compound”on pathomorphology and lung index in PF rats.
Through observing general status of PF rats (such as weight, movement and respiration etc),
Lung index and the changes in pathomorphology (HE and MASSON stain), studying the effects of”strengthening earth to support metal and stasis-resolving compound”on PF rats, and then comparing the effects of the herbal compound according to statistic data.
The results showed as following: Exclude the normal group, other groups in PF rats had the phenomena of weight reducing, movement decreasing, less eating and lung index increasing. Under the microscope, alveolitis and collagen deposition were observed in different degrees among lung interstitial by HE and MASSON stain. After the herbal compound treatment, the general status of PF rats were improved, lung index reduced, and alveolitis and fibrosis relieved on pathomorphology.
The results:⑴The PF rat model induced by BLM was successfully duplicated.⑵The herb compound of“strengthening earth to support metal and stasis-removing”can improve the degree of the alveolitis and fibrosis in PF rats.
2 The study on the effects of”strengthening earth to support metal and stasis-resolving compound”on contents of HYP in PF rats.
Though the research on the effects of”strengthening earth to support metal and stasis-resolving compound”on the contents of HYP in PF rats, discussing the change about contents of HYP in the process of PF. HYP is one of the main components in the collagen of body, and very few in the elastin, whereas no in the other protein. Therefore, HYP is the endemic components of collagen fiber. So that it is the diagnostic marker of PF and can judge the degree of PF.
The results showed as following: Besides the normal group, the deposit of collagen appeared obviously in the lung tissues in the other groups. Data suggested that the contents of HYP increase in different degrees, furthermore the degree of PF aggravate gradually with the lapse of time. After the herbal compound treatment, HYP contents reduced, thus indirectly decreasing the contents of collagen, and acting on relieving the effect of PF.
The results:⑴The PF rat model induced by BLM was successfully duplicated.⑵The herb compound of”strengthening earth to support metal and stasis-resolving”can reduce the HYP contents, so that it can improve the degree of fibrosis in PF rats.
3 The study on the effects of“strengthening earth to support metal and stasis-resolving compound”on the expression of TGF-β1 and MCP-1 protein in PF rats.
Through the method of immunohistochemistry, combining with image analysis, we observed the expression of TGF-β1 and MCP-1in lung tissues at different phases, further discussing the mechanism of PF from immunohistochemistry.
The results showed as following: In the different time, the expression of TGF-β1 and MCP-1 protein in lung tissues are higher than the normal group. After“strengthening earth to support metal and stasis-resolving compound”treatment, the expression of TGF-β1 and MCP-1 protein all reduced in different degrees, which suggested that the herbal compound may be through inhibiting the high expression of TGF-β1 and MCP-1 protein, therefore making the degree of PF reduce.
The results: After the herbal compound of“strengthening earth to support metal and stasis-resolving”, the above makers may be improved effectively, so decreasing the degree of PF from immunohistochemistry.
4 The study on the effect of the expression of TGF-β1mRNA in lung tissues
In this study, using the method of RT-PCR and image analysis, we compare the expression of TGF-β1mRNA in lung tissues at different phases in every group, further discussing the mechanism of the herbal compound of”strengthening earth to support metal and stasis-resolving”from molecular biology.
The results as following: TGF-β1mRNA expressed in lung tissues on different stages of PF, and there was significant difference in the expression intensity between the normal group and other groups. After“strengthening earth to support metal and stasis-resolving compound”treatment, the expression of TGF-β1mRNA in lung tissues was improved in different degrees, which suggested that the herbal compound may inhibit the expression of TGF-β1mRNA on PF rats.
The results: After the herbal compound of“strengthening earth to support metal and stasis-resolving”treatment, the expression of TGF-β1mRNA obviously decreased, thus reducing the degree of PF from molecular biology.
In summary, this study, by using BLM to induce PF model on rats, we apply the herbal compound of”strengthening earth to support metal and stasis-resolving”to treat the PF rats, thus discussing the effects of the herbal compound on PF rats. The results suggest that the herbal compound can effectively improve the abnormal status, reduce the content of HYP, suppress the high expression of TGF-β1mRNA, TGF-β1 and MCP-1 in lung tissues, thus relieving the degree of alveoli and fibrosis and blocking the pathological process, which provide the solid theoretical foundation for the clinical treatment in future.
中医理论多将肺纤维化归为“咳嗽”“喘证”、“肺痹”等范畴,认为肺纤维化的病位在肺,而与多脏器有关,病机多为正虚邪实。本实验结合古今文献的研究,根据五行相生等的中医基础理论及长期的临床观察,认为该病病位虽然在肺,但与脾密切相关,病机以虚、瘀为关键,提出了肺纤维化“脾虚血瘀”的中医病机假说,由此针对肺纤维化主要病理变化,采用培土生金,活血化瘀的基本治法,拟定培土生金化瘀中药复方加减变化治疗该病,在临床实践中取得了较为满意的效果。为了进一步探讨该复方治疗肺纤维化的作用机理,我们采用该药复方治疗肺间质纤维化大鼠,选择相关分子生物学指标,通过现代先进的实验技术,从不同层面、不同水平动态观察中药复方对实验性肺纤维化的影响,进而探讨其治疗肺纤维化的机理,为肺纤维化的临床治疗提供理论依据。
本实验采用博莱霉素复制大鼠肺纤维化模型,分别在7天、14天、28天三个时间点,研究培土生金化瘀中药复方对肺纤维化大鼠的干预作用,从分子生物学、免疫学、病理学等不同层面来探讨该中药复方的作用机制。实验研究共分为四部分:
1培土生金化瘀中药对博莱霉素所致大鼠肺纤维化的肺组织形态及肺系数的影响
通过对模型动物一般状况的观察(如体重、活动、饮食、及呼吸等)及对肺重、肺系数、病理形态学的研究(HE染色、MASSON染色),通过进行数据统计来比较培土生金化瘀中药的作用效果,以观察培土生金化瘀中药复方对肺间质纤维化大鼠的影响,。
结果显示:除了正常组外,其余各组大鼠均有不同程度的活动减少、体重下降、饮食减少以及肺系数的增加;肺组织HE染色和MASSON染色均可见程度不同的肺泡炎和细胞外基质沉积。经培土生金化瘀中药复方治疗后大鼠一般状态有所好转;肺系数有所减少;病理形态学显示肺泡炎及肺纤维化均有不同程度的改善。
结论:(1)博莱霉素诱导大鼠肺纤维化模型成功。
(2)培土生金化瘀中药复方能在一定程度上改善肺间质纤维化大鼠的肺泡炎及肺纤维化。
2培土生金化瘀中药对博莱霉素所致大鼠肺纤维化羟脯氨酸含量影响的机制研究
通过对肺纤维化模型大鼠羟脯氨酸含量影响的实验研究,探讨在肺间质纤维化形成过程中羟脯氨酸含量的变化情况。羟脯氨酸是机体胶原蛋白的主要成分之一,在弹性蛋白中含量极少,而在其它蛋白则不存在[4]。因此,羟脯氨酸为胶原纤维所特有,以此作为肺纤维化的指标,可以判断肺纤维化的程度。
结果显示:除正常组外其余各组大鼠肺组织胶原沉积明显,数据显示羟脯氨酸含量有不同程度的增加,且纤维化程度随时间的推移而持续加重。经培土生金化瘀中药复方治疗后羟脯氨酸含量有所下降,从而间接地降低肺组织中胶原的含量,起到了减轻肺纤维化的作用。
结论:培土生金化瘀中药复方可减少肺间质纤维化大鼠的羟脯氨酸含量,从而使纤维化大鼠的纤维化程度有所改善。
3培土生金化瘀中药对肺间质纤维化大鼠肺组织中TGF-β1及MCP-1蛋白表达影响的机制研究
通过免疫组织化学染色的方法,结合图像半定量分析技术,研究TGF-β1及MCP-1不同时期的蛋白表达,从免疫组化方面进一步探讨了培土生金化瘀中药对肺纤维化的作用机制。
结果显示:在肺纤维化发展的各个时间点,TGF-β1及MCP-1蛋白在肺组织中的表达均较正常组明显升高。经培土生金化瘀中药复方治疗后,TGF-β1及MCP-1蛋白表达有不同程度的降低,提示培土生金化瘀中药复方可能通过抑制TGF-β1及MCP-1在肺组织中的异常高表达,从而使肺纤维化程度有所减轻。
结论:培土生金化瘀中药复方可调节TGF-β1及MCP-1蛋白的表达,从免疫组化方面使肺纤维化的程度有所减轻。
4培土生金化瘀中药对肺间质纤维化肺组织TGF-β1mRNA基因表达影响的机制研究
本实验采用RT-PCR的方法,结合图像分析技术,比较各组肺组织在不同时间点上TGF-β1mRNA的基因表达,从分子生物学方面进一步探讨了培土生金化瘀中药的作用机制。
结果显示:在肺纤维化发展的各个时间点,TGF-β1mRNA在肺组织中均有表达,且强度与正常组比较有显著性差异。经培土生金化瘀中药复方治疗后,TGF-β1mRNA在肺组织中的表达有不同程度的下调,提示培土生金化瘀中药复方可抑制纤维化大鼠的TGF-β1mRNA基因表达,从而改善纤维化,达到预防与治疗的目的。
结论:培土生金化瘀中药复方可下调TGF-β1mRNA在肺组织中的基因表达,从而表明该中药复方可在分子生物学水平减轻肺纤维化的程度。
综上所述,本课题采用博莱霉素复制肺纤维化动物模型,应用培土生金化瘀中药复方对肺纤维化大鼠进行干预治疗,从不同层面、不同水平研究培土生金化瘀中药复方对肺纤维化大鼠的作用机制。结果表明,该中药复方能有效的改善肺纤维化的病理状态、降低羟脯氨酸含量、抑制了TGF-β1mRNA、TGF-β1及MCP-1蛋白在肺内的高表达,从而减轻了肺纤维化大鼠的肺泡炎及肺纤维化程度,阻断了纤维化的病理进程,为今后肺纤维化的临床治疗提供了更为坚实的理论依据。
Pulmonary interstitial fibrosis (PF) is a kind of disease characterized by diffusion, infiltration and fibrosis as a common outcome of many interstitial lung diseases. Constantly, the course of PF progressively develops. Its pathological features are the chronic inflammation leading to persistent injury of alveolar cell, over reproduction of lung fibroblast (FB) and excess deposition of extracellular matrix (ECM). It′s well known, the injury of tissues is usually accompanied by inflammation and repairing course. If the scope of injury is small, tissues can recover to normal structure and function, such as the infection reducing by most of bacteria and virus. Otherwise when the range is relatively big or recurrence, the frequent repairing will lead to fibrosis or scar formation, which will influence flexibility and respiratory function and induce the patient died of heart and lung failure as well as hypoxemia. As result of its pathogenesis is not thoroughly clear so far, there is no specific medicine in clinic. The traditional medicine is mainly glucocorticoid and immunosuppressant, delaying the course of PF through relieving inflammation. But to the patient diagnosed as PF in clinic, not only fibrosis has been developing and the disease condition had been developing continuously, but also the curative effect is still dissatisfactory and obvious adverse reactions were induced after long application. Therefore at present, the urgent question is to develop the better effect and high security medicine for PF.
PF is mostly divided into the category of“Consumptive Lung Disease”“Bi syndrome of the lung”in TCM, believed that the location of PF is in lung, also relating to multiple viscera, and its pathogenesis due mostly to deficient vitality and excessive evil. Through combining with the study on the ancient and modern literature and the long clinical observation, we considered that this disease is belonged to the category of“Consumptive Lung Disease”, and the ill location lies in lung, but closely connective with spleen, and the key of pathogenesis is deficiency and stasis, so we put forward the hypothesis of deficiency of spleen and blood stasis. Furthermore combining with the theory of TCM, we also believes that invigorating spleen and lung, promoting blood and stasis-resolving is the basically big method, and applies the modification of the herbal compound of strengthening earth to support metal and stasis-resolving in treating PF, and has achieved the satisfactory effects in clinic. In order to further explore the effect of the herbal compound on PF, we apply the compound to treat PF rats, choose relative molecular biological markers, and use advanced experimental technique, observing the effect of the herbal compound on PF rats from different levels and angels, which provide theory basis for treating PF in clinic.
In this experiment, we apply BLM to induce the PF model on rats, studying the effect of“strengthening earth to support metal and stasis-resolving compound”on PF rats, at the time of 7d,14d and 28d, exploring the mechanism of the herb from the different levels and angels such as molecular biology, immunity and pathology etc,so as to find the more effect medicines for the clinic. The experimental research consists of four parts as following:
1 The effects of“strengthening earth to support metal and stasis-resolving compound”on pathomorphology and lung index in PF rats.
Through observing general status of PF rats (such as weight, movement and respiration etc),
Lung index and the changes in pathomorphology (HE and MASSON stain), studying the effects of”strengthening earth to support metal and stasis-resolving compound”on PF rats, and then comparing the effects of the herbal compound according to statistic data.
The results showed as following: Exclude the normal group, other groups in PF rats had the phenomena of weight reducing, movement decreasing, less eating and lung index increasing. Under the microscope, alveolitis and collagen deposition were observed in different degrees among lung interstitial by HE and MASSON stain. After the herbal compound treatment, the general status of PF rats were improved, lung index reduced, and alveolitis and fibrosis relieved on pathomorphology.
The results:⑴The PF rat model induced by BLM was successfully duplicated.⑵The herb compound of“strengthening earth to support metal and stasis-removing”can improve the degree of the alveolitis and fibrosis in PF rats.
2 The study on the effects of”strengthening earth to support metal and stasis-resolving compound”on contents of HYP in PF rats.
Though the research on the effects of”strengthening earth to support metal and stasis-resolving compound”on the contents of HYP in PF rats, discussing the change about contents of HYP in the process of PF. HYP is one of the main components in the collagen of body, and very few in the elastin, whereas no in the other protein. Therefore, HYP is the endemic components of collagen fiber. So that it is the diagnostic marker of PF and can judge the degree of PF.
The results showed as following: Besides the normal group, the deposit of collagen appeared obviously in the lung tissues in the other groups. Data suggested that the contents of HYP increase in different degrees, furthermore the degree of PF aggravate gradually with the lapse of time. After the herbal compound treatment, HYP contents reduced, thus indirectly decreasing the contents of collagen, and acting on relieving the effect of PF.
The results:⑴The PF rat model induced by BLM was successfully duplicated.⑵The herb compound of”strengthening earth to support metal and stasis-resolving”can reduce the HYP contents, so that it can improve the degree of fibrosis in PF rats.
3 The study on the effects of“strengthening earth to support metal and stasis-resolving compound”on the expression of TGF-β1 and MCP-1 protein in PF rats.
Through the method of immunohistochemistry, combining with image analysis, we observed the expression of TGF-β1 and MCP-1in lung tissues at different phases, further discussing the mechanism of PF from immunohistochemistry.
The results showed as following: In the different time, the expression of TGF-β1 and MCP-1 protein in lung tissues are higher than the normal group. After“strengthening earth to support metal and stasis-resolving compound”treatment, the expression of TGF-β1 and MCP-1 protein all reduced in different degrees, which suggested that the herbal compound may be through inhibiting the high expression of TGF-β1 and MCP-1 protein, therefore making the degree of PF reduce.
The results: After the herbal compound of“strengthening earth to support metal and stasis-resolving”, the above makers may be improved effectively, so decreasing the degree of PF from immunohistochemistry.
4 The study on the effect of the expression of TGF-β1mRNA in lung tissues
In this study, using the method of RT-PCR and image analysis, we compare the expression of TGF-β1mRNA in lung tissues at different phases in every group, further discussing the mechanism of the herbal compound of”strengthening earth to support metal and stasis-resolving”from molecular biology.
The results as following: TGF-β1mRNA expressed in lung tissues on different stages of PF, and there was significant difference in the expression intensity between the normal group and other groups. After“strengthening earth to support metal and stasis-resolving compound”treatment, the expression of TGF-β1mRNA in lung tissues was improved in different degrees, which suggested that the herbal compound may inhibit the expression of TGF-β1mRNA on PF rats.
The results: After the herbal compound of“strengthening earth to support metal and stasis-resolving”treatment, the expression of TGF-β1mRNA obviously decreased, thus reducing the degree of PF from molecular biology.
In summary, this study, by using BLM to induce PF model on rats, we apply the herbal compound of”strengthening earth to support metal and stasis-resolving”to treat the PF rats, thus discussing the effects of the herbal compound on PF rats. The results suggest that the herbal compound can effectively improve the abnormal status, reduce the content of HYP, suppress the high expression of TGF-β1mRNA, TGF-β1 and MCP-1 in lung tissues, thus relieving the degree of alveoli and fibrosis and blocking the pathological process, which provide the solid theoretical foundation for the clinical treatment in future.
引文
1.Razzaque MS, Taguchi T. Pulmonary fibrosis: Cellular andmolecular events. Pathol Int,2003;53:133-145.
2.Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med,2001;110:278-282.
3.Geiser T. Idiopathic pulmonary fibrosis-a disorder of alveolar wound repair? Swiss Med Weekly,2003;133:405-411.
4.柴文戍,李永春等.博莱霉素致肺纤维化大鼠形态学变化的实验研究.中国实验动物学报. 2003;11(2):80.
5.侯显明,于润江.间质性肺病学.第一版.北京:人民卫生出版社. 2003: 222.
6.牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志.2006;26(12):928.
7. Margett s PJ,Bonniaud P,Liu L,et al. Transient overexpression of TGF-beta1 induces epit helial mesenchymal transition in the rodent peritoneum. J Am Soc Nep hrol, 2005;16(2):425-436.
8.邵长周,陈小东,蔡映云.细胞因子在肺纤维化形成中的作用及对治疗方法的启迪.实用心脑肺血管病杂志.2001;9(2):116.
9.Hasegaua M,Sato S,Takehara K,Augmented production chemokines( monocyte chemotatic protein-1, CP-1 ),macrophage inflammatory protein-1alpha (MIP-αand MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-αmay be involved in the development of pullmonary fibrosis.Clin Exp Immunol.1999;117(1):159-165.
10.Standiford TJ, Rolfe MW, KunkelSL, etal. Macrophage inflammatory protein-1αexpression in interstitial lung disease. J Immunol. 1993;151:2852-2863.
11.崔晓丽.培土生金法在呼吸系统疾病中的应用.中医药临床杂志,2005;17(6): 532.
12.赵洪文,彭璐,吕长俊,等.肺纤维化大鼠BALF中细胞成份与肺组织病理的动态研究[J].中国医科大学学报.1997;26(5):463.
13.Kumar RK. Morphological methods for assessment of fibrosis. Methods Mol Med. 2005; 117:179-188.
14.Szapiel SV,et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse[J]. Am Rev Respir Dis. 1979;120(4):893-899.
15.Snider GL,Hayes JA. Korthy AL.Chronic interstitial pulmonary fibrosis produced in hamsters endotracheal bleomyein: pathology and stereology[J]. Am Rev Respir Dis.1978;117(6):1009-1108.
16.刘介眉,严庆汉,路英杰,等.染液的配制和染色方法[M].病理组织染色的理论方法和应用.北京人民卫生出版社.1983;22:36-38.
17.戴令娟,候杰,蔡后荣,等.肺纤维化动物模型肺组织形态定量分析[J].南京铁道医学院学报.1996;15(1):24-27.
18.金洪,田英麟,姚汉德,等.汉防己甲素阻断平阳霉素所致肺间质纤维化的实验研究〔J〕中华结核和呼吸杂志.1991,14(6):359.
19.夏宇.肺纤维化动物模型建立及评价的研究进展.新疆医科大学学报.2005;28 (6): 510–511.
20.苗维纳,等.丹参对实验性肺纤维化小鼠病理变化和转化生长因子-β表达的影响[J].中药药理与临床.2003;19(5):24.
21.魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏系数和肺胶原含量的变化[J].工业卫生与职业病.2001;27 (6):351-353.
22.李才,张一宁,牛俊奇,等.器官纤维化基础与临床[M].北京:人民卫生出版社. 2003:188.
23.南京建成生物工程研究所.HYP试剂盒使用说明.
24.Nagao T, Nagai S, Hiramoto Y, et al. Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia[J]. Respiration,2002;69(5):413.
25.Donald N. Cook, David M. Brass, et al. A Matrix for New Ideas in Pulmonary Fibrosis[J].Am J Respir Cell Mol Bio1,2002;27:122.
26.White E S, Lazar M H, Thannickal V J. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis[J].JPathol, 2003;201(3):343.
27.Piguet P F. Inflammation in idiopathic pulmonary fibrosis[J].Am JRespir Crit Care Med,2003;167(7):1037.
28.罗慰慈.现代呼吸病学〔M}.北京:人民卫生出版社.1997: 119.
29.徐峥嵘.细胞因子及其特异性抑制剂与肺纤维化的治疗[J].中国公共卫生.2005;21(6): 750-753.
30.Brent E Van Hoozen,Katharine L Grimmer,Gregory P Marelich,etal. Early phase collagen synthesis in lungs of rats exposed to bleomycin [J].Gregory P Marelich,et in Toxicology.2000;147(1):1-13.
31.S N Iyer,G Gurujeyalakshmi, S N Giri. Effect of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis[J].The Journal of Pharmacology and Experimental Therapeutics.1999; 289(1):211-218.
32.魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏器系数和肺胶原含量的变化[J].工业卫生与职业病. 2001;27(6):351-353.
33.雷丰峰,等.转化生长因子与肺纤维化[J].新医学.2003;34(11):715.
34高丽,等.细胞因子与肺间质纤维化相关研究进展.内蒙古医学院学报.2006;12 (28): 36-37.
35.李学军,崔社怀.肺纤维化大鼠血浆MCP-1α、MCP-1水平动态变化的观察.解放军医学杂志.2001;26(10):745.
36.李学军,崔社怀.三七总苷抗肺纤维化的实验研究[J].药物研究, 2004, 13 (4): 34-35.
37.辛洪涛,刘庆华,张欣,等.芪丹颗粒剂治疗肺间质纤维化的临床研究.山东医药,2002; 42(19):20-21.
38.武汉博士德生物工程有限公司.即用型SADC免疫组化染色试剂盒使用说明书,2006.
39.刘芳,徐启勇,叶燕青.撷沙坦对肺纤维化模型的干预作用及其对肝细胞生长因子表达的影响[J].中华结核和呼吸杂志.2002;8(7):479-483.
40.黄晓红.MCP-1及其在疾病发生中的作用.国外医学呼吸系统分册.1995;15(4):170-172.
41.魏路清,董彦.肺纤维化发病机制及治疗策略的新观念.国外医学呼吸系统分册.2003;23,(1):38-41
42.Meltzer MS,et al. Cancer Rr,,1977;37:721-725.
43.Yoshimura T,et al.J Exp Med.1989;169:1449-1459.
44.Yashimura T,et al.J Immuno1,1989;142:1956-1962.
45.黄晓红.MCP-1及其在疾病发病中的作用.国外医学呼吸系统分册.1995;15(4):170.
46.Zhang K, Gharaee-Kermani M, Jones ML, etal. Lung monocyte chemoattractant protein -1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol, 1994 ; 153:4733.
47.Snga M,Iyonaga K,Ichiyasn H,et al. Clinical significance of MCP-1 levels in BALF and serum in patients withinterstitil lung diseases. Eur Respir J,1999;14:376.
48.曾钧,宋烈昌,金行中等.地塞米松对肺纤维化大鼠肺单一核细胞趋化蛋白-1基因表达的影响.中国药理学通报.2001;17(l):73-5.
49.Altman LC,et al.J Immuno1.1973;110:801-810.
50.张志琴,呼海燕,司军强. TGF-β在肺纤维化中的作用.农垦医学,2002,24(6):434-435.
51.董翔林,马少林.转化生长因子β在纤维化疾病中的研究与应用.中国临床康复,2004;8(35):8050.
52.崔勇丽等,肺纤维化与细胞因子.国外医学卫生学分册,2002;29(6):325.
53. CokerRK, et al. [J]. Thorax, 2001;56(7):549-556.
54.邵长周等.细胞因子在肺纤维化形成中的作用及对治疗方法的启迪.实用心脑肺血管病杂志,2001;9(2):114.
55.Broeklmann TJ,Limper AH,Colby TV,et al. Transforming growth factorβ1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Prc Natl AcadSci USA,1991;88:6642.
56.Gurujeyalakshmi G,Hollinger MA,Giri SN,et a1. Regulation of transforming growth factor mRNA expression by taurin and niacin in the bleomycin Hamster model of lung fibrosis[J].Am J Repir Cell Mol Bio1,1998;18:33.
57.宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重塑及生长因子的研究[J].中华结核和呼吸杂志,2001;24:283-287.
58.Brass DM,Hoyle GW,Poovey HG,et al. Reduced tumor necrosis factor-alpha and transforming growth factor-betal expression in the lungs of inbred mice that failto develop fibroproliferative lesionsc onsequentt o asbestose xposure[J}.Am J Pathol,1999;154 (3):853-862.
59.李江,武芳,黄茂,等.川芎秦注射液对博莱霉素致肺纤维化大鼠转化生长因子干预作用的研究.时针国医国药,2007;18(6):1289.
60.Coker RK,Eur Respir J,Laurent GJ. Pulmonary fibrosis: cytokines in the balance[J].1998;11:1218-1221.
61.张必萌,等.转化生长因子的生物学效应与纤维化疾病的研究.现代康复.2001; 5 (1) 76-77.
62.Roberts AB, Piek E, Bottinger EP, et al. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? [J].Chest 2001 ; player120 (1supple):43s-47s.
63.Vaillant P, Menard 0, Vignaud JM, The role of cyt.okines in human lung fibrosis[J).Monaldi Arch Chest Dis,1996;51(2):145-152.
64.Sheppard D.Pulmonary fibrosis:a cellular overreaetion or a failure of communication?[J].Clin Invest,2001;107 (12):1501-1502.
65.Khalil S. Regulation of Alveolar Macrophage Transforming Growth Factor-βSecretion by Corticosteroids in Bleompcin-induced Pulmonary inflammation in the Rat[J].J Glin Invest, 1993; 92(4):1812-1818.
66.陈金亮,赵燕峰.肺痿证治渊源探讨[J].陕西中医.2001;(4):220.
67.王永炎,晁恩祥.今日中医内科(中卷)[M].北京:人民卫生出版社,2000:320- 322.
68.侯杰.肺系慢性疾病[M].南京:江苏科技出版社,1984:353.
69.智屹惠.曹世宏教授论治肺间质纤维化[J].南京中医药大学学报(自然科学版) .2001; 17 (3):185-186.
70.张炜,毕小利,马文欢.生地对特发性肺间质纤维化基质重建调控作用的实验研究[J].中国中医基础医学杂志. 2001; 7(6): 34-36.
71.杨和春.浅谈肺系疾病的上盛下虚证治[J].湖北中医杂志.1989;11(5):33-34.
72.宋建平.《金匮要略》所论短气与特发性肺纤维化[J].南京中医药大学学报. 1998; 14 (6): 326-327.
73.张天蒿,马君,韩镭.赵子贤辨治特发性肺间质纤维化经验.浙江中医杂志. 1998; 33(3):102.
74.龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点.浙江中医杂志. 2001; (4) : 139.
75.王海彤,武维屏.中医药治疗弥漫性肺间质纤维化信息讨论.中国中医药信息杂志.1996; 3(7):25.
76.朱玉龙,徐卫方.中医对“肺间质纤维化”的认识.河南中医. 2005;25(12):37.
77.要全保.慢性阻塞性肺病从脾论治初探.中医函授通讯.1999;18(5):15.
78.危北海.有关脾胃学说的理论探讨及临床诊治经验.中医药学刊. 2006; 24 (7): 1191.
79.刘洁文,齐淑玲.血瘀证实质和活血化淤药物作用机理的研究.中医药通报.2003;2(1):4.
80.Ortiz La,lasky J,Hamilton RF,et al.Expressinn of TNF and necessity of TNF - receptors in bleomycin-induced lung injury in mice. Exp Lung Res,1998,24 (6):721-743.
81.Uubaybo,BA. Role of Tumor necrosis factor-in regulating fibrotic lung replair Res. Commun. Mol. Pathol. Pharmacol,1998,l0(1):69.
82.侯杰.肺系慢性疾病[M].南京:江苏科技出版社,1984:353.
83.崔晓丽.培土生金法在呼吸系统疾病中的应用.中医药临床杂志.2005;17(6):532.
84.汪绮石.汪绮石脾胃学术思想探析.中华医史杂志.2002;32(1):39.
85.沈湘妹.培土生金法治疗小儿间质性肺炎.湖北中医杂志.2000;22(11):29.
86.张向前,刘晖.《金匮要略》非脾之疾从脾论治浅探.中国民间疗法.2005;13(12):5.
87.沈映君.中药药理学.第一版.北京:人民卫生出版社.2000:880-881.
88.焦红军.党参的药理作用及其临床应用.药物与临床. 2005;25(4):92.
89.李秋怡,等.川芎的化学成分及药理研究进展.时珍国医国药.2006;17(7):1299.
90.王良兴.川芎嗪对组胺和乙酰胆碱所致豚鼠气管条收缩作用的影响[J].温州医学院学报.1995;25(3):158.
91.李鲁扬,唐占府,孔令钧.复方丹参注射液对冠心病患者血小板活化率的影响[J].山东中医杂志.2001;20(4):20-20.
92.姚富和,张义善,黄麦华,等.复方丹参滴丸治疗稳定型心绞痛50例[J].山东中医杂志.2002;21(3):147-147.
93.孙艳芳,吕晓,韩广明,等.复方丹参注射液治疗糖尿病多发性末梢神经病变34例[J].山东中医杂志.2002;21(8):472-472.
94.王莉,赵长云,赵国瑞,等.复方丹参注射液加黄芪注射液治疗冠心病58例疗效观察[J].中国中医药科技.2002;9(4):252-252.
95.殷静先.白术药理研究进展.时珍国医国药.2000;11(6):572.
96.中华人民共和国药政管理局.现代实用本草.第1版[M].北京:人民卫生出版社.1997∶248.
97.缪竞诚,等.梭甲基获荃多糖对淋巴细胞产生细胞因子的促诱生作用.中成药.1999; 21(12):639。
98.吕苏成,等.茯苓多糖对正常及荷瘤小鼠免疫功能的影响.第一军医大学学报.1990;10(3):267.
99.严晓红,欧阳静萍,涂淑玲,等.当归对氧化低密度脂蛋白所致血管内皮细胞损伤的保护作用[J].湖北医科大学学报.1999;20(3):181-183.
100.夏泉,等.当归的药理作用研究进展.时针国医国药.2004;15(3):3-4.
101.王访,苏耀海.甘草的药理作用及临床应用.时珍国医国药.2002;13(5):303-304.
1.Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement [J] . Am J Respir Crit Care Med, 2000, 161(Pt 1): 646-664.
2.李戎,问智勇,李文军,等.肺纤维化发生与防治机制的重要因素—细胞因子作用机制研究.中国中医药.2004; 6: 23.
3.Sullivan DE, Ferris M,Pociask D, et alTumor necrosis factor-ninduces transforming growth factor-β1 expression in lungfibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol, 2005. 32:342-349.
4.李才,张一宁,牛俊奇,等.器官纤维化—基础与临床.第1版.北京:人民卫生出版社,2003.
5.Huaux F, Liu T, MeGacry B, et al. Dual roles of IL - 4 in lung injury and fbrosis. Immunol ,2003. 170:2083 - 2092.
6.Bresser P, Jansen HM, Weller FR, et al. T-ceB activation in the lungs of patiens with systemic sclerosis and its relation with pulmonary fibrosis. Cheat, 2001, 120:66-68.
7.Huaux F, Louahed J, Hudspith B, et al. Role of interleukin - 10 in the lung response to silica in mice. Am J Respir Cell Mol Bi-o1, 1998 , 18:51- 59.
8.Barbadn V, Xing Z, Delos M, et al. Pul-monery overexpression of IL- 10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol , 2005,288:L841- L848.
9.Brunetti G, Delmastro M, Fonte R, et al. Immunocytological and mineralogical study of bronchoalveolar lavage in a group of subjects exposed to asbestos. G Ital Med Lav Ergon, 2003, 25;152 - l60.
10.Sakamoto H, Zhao LH, Jain F, et al. IL-12p40 mice treated with intratracheal bleomycin exhibit decreased pulmonary inflam-oration and increased fibrosis. Exp Mol Pathol , 2002, 72:1- 9.
11.Barbuleacu K, Backer C, Schlaak JF, et al. IL-12 and IL-18 differentially regulate the tranacriptional activity of the human IFN - gamma promoter in primary CD4+Tlymphocytea. J Immunol, 1998, l60 : 3627 - 3642.
12.李永春,何冰,陈建,等.核因子κВ在大鼠肺纤维化中的活性和表达及红霉素治疗对它的影响.北京医科大学学报.2000; 32:14-17.
13.李学军,崔社怀.三七总皂甙对大鼠肺纤维化过程中血浆MIP-1α、MCP-1含量的影响.第三军医大学学报.2003;25(6)522-524.
14.Standiford TJ,Rolfe MW,Kunkel SL,et al.Macrophage inflammatory protein -1αexpression in interstitial lung disease. J Immunol.1993,151: 2852 ~2863.
15.Zhang K, Kermani MG, Jones ML, et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin induced pulmonary fibrosis.J Immunol.1994,153:4733 ~4741.
16.Sheppard D. Pulmonary fibrosis ; a cellular overreaction or a failure of communication? J Glin Invest, 2001,.107:1501-1502.
17.Bingisser R, Stey C, Welter M, et al. Appotosis in human alveolar maemphaRea is induced by endotoxin and is modulated by cylokines. Am J Respir Cell Mol Biol, 1996,15: 64-70.
18.Willis BC, Liebler JM, Luby-Phelps K, etal. Induction of epithelial- mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am J Pathol ,2005 , 166: 1321- 1332.
19.Silvers MR, Sempowski GD, Phipps RP. Expression of TGF-beta isoforms by Thy-1+and Thy-1-pulmonary Gbrohlaw subsets; evidence for TGF- data as a regulator of IL-1-dependent stimulation of IL-6. Lymphokine Cytokine Res, 1994, 13;227.
20.吴晓梅,王欣燕,陈复辉.两种细胞因了与特发性肺纤维化的关系.中国危重病急救医.2003; 6 : 363.
21.娄克俭.肺纤维化发病机制的研究进展.临床医学.2005;8(4):33
22.曹名波.基质金属蛋白酶及其抑制物与肝纤维化.国外医学消化系疾病分册. 2005; 25:114-117.
23.马万里,李元桂,辛建保.基质金属蛋白酶及金属蛋白酶组织抑制剂在肺纤维化中的变化.华中科技大学学报(医学版).2002;31; 527-533.
24.Gurujeyalashmi G,Giri SN. Molocular mechanism of antifibrotic effect of inter-ferongamma in belomycin-mouse model of lung fibrosis: down regulation of TGF-beta and procollagen I and 11I gene expression. Exp Lung Res, 1995. 21: 791-809
25.Ziesche H, Hotbauer E, W ittmann K,et al. Apreliminary study of long term treatment with interferon gamma-1b and lowdose prxlnisolone in patients with idiopathic pulmonary Fbrosis. Nengl 7 Med, 1999, 341: 1264-1269
26.Millar A. Anti-cytokine therapy in fibrossing alveoitis: where are we now? Respir ReRes, 2000, 1: 3-5.
27.erohand-Adam S, Plentier L, Bernuau D, et al. Kerntinocyte growth factor expression by fibroblasta in pulmonary fibrosis; poor response to interleukin-1 ? Am 1 Respir Cell Mol Biol, 2005, 32; 470-477.
28.Baraxzone C, Donati VR, Rochat AF, et al.Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol ,1999, 154:1479-1487.
29.Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to acid instiVation in rata. Am1 Respir Cell Mol Biol, 1996,15:433.
30.Viget NB, Guery BP, Ader F, et al. Keretinacyte growth factor protects against pseudomonas aenrginose2 induced lung injury. Am 1 Physiol Lung Cell Mol Physiol, 2000, 279: L1199-L1209.
31.陈刚,吴允孚,周彩存.角质细胞生长因子和肝细胞生长因子在肺感染及损伤修复中的作用,医学综述.2005; 11: 936– 938
32.GulsvikA, KjelsbergA, Bergmann, et al. High 2 dose intravenous methyl prednisolone pulse therapy asinitial treatment incryptogenic fibrosis singal veolitis: apilotstudy[J].Respiration, 1986, 50: 252.
33.Douglas W, Ryu J H , wensen SJ , et al . Colchicine versus prednisone in the treatment of idiopat hic pulmonary fibrosis: a randomized prospective study. A m J Respi r Crit Care Med , 1998 , 158 (1): 220-226.
34.Molteni A, Moulder J E, cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensinⅡtype
35.Desaki M ,Okazaki H ,Sunazuka T ,et al ,Molecular mechanism of anti2inflammatory action of eryt hromycin in human bronchia epit helial cells : possible role in the signaling pat hway t hat regulates nuclear factor2kappaB activation. Antimi crob Agents Chemother,2004,48(5):1581-1585.
36.Li Y, Azuma A , Usuki J , et al . EM703 improves bleomycin induced pulmonary fibrosis in mice by t he inhibition of TGF-beta signaling in lung fibrosis. Respir Res, 2006, 7 (1) :18-20.
37.Behr J, Maier K, Degenkolb B, et al . Antioxidative and clinical effects of high2dose N2acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med, 1997, 156 (6): 1897-1901.
38.Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis wit h a new antifibrotic agent, pirfenidone: results of a prospective, openabel PhaseⅡstudy. Am J Respir Crit, Care Med, 1999, 159 (4 pt 1): 1061-1064.
39.Azuma A, Expectation of new treatments for idiopathic interstitial pneumonias. Nippon Ronen Igakkai Zasshi, 2005, 42 (1): 27-30.
40.Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long term treatment wit h interferon Gamma21b and low dose prednisolone in patients wit h idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2004, 31 (6): 679-686.
41.Wang Q, Wang Y, Hyde DM , et al . Reduction of bleomycin induced lung fibrosis by transforming growt h factor beta soluble receptor in hamsters. Thorax, 1999, 54 (9): 805-812.
42.Kolb M , Margetts PJ , Galt T , et al . Transient t ransgene expression of decorin in the lung reduces t he fibrotic response to bleomycin. Am J Repir Crit Care Med, 2001, 163 (3 pt 1): 770-777.
43.李伟杰,齐景宪.肺纤维化治疗新进展.医师进修杂志.1999; 2(22): 52-55
44.牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志.2006; 12,(26): 928-931.
45.智屹惠.曹世宏教授论治肺间质纤维化[J].南京中医药大学学报(自然科学版) .2001; 17 (3):185-186.
46.张炜,毕小利,马文欢.生地对特发性肺间质纤维化基质重建调控作用的实验研究[J].中国中医基础医学杂志. 2001; 7(6): 34-36.
47.宋建平.《金匮要略》所论短气与特发性肺纤维化[J].南京中医药大学学报. 1998; 14 (6): 326-327.
48.张天蒿,马君,韩镭.赵子贤辨治特发性肺间质纤维化经验.浙江中医杂志. 1998; 33(3):102.
49.龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点.浙江中医杂志. 2001; (4) : 139.
50.孟磊,陈军,高彩霞.活血祛瘀法为主治疗特发性肺纤维化[J].河南中医. 2002; 22(4): 58-59.
51.王健.肺纤维化的实验研究及HRCT[J].国外医学·临床放射学分册. 1998; (2): 74-77.
52.Zia S,Hyde D M, Giri S N.Development of a bleomycin hamster model of subchronic lung fibrosis[J]. Pathology,1992,24:155.
53.高燕,雍政,黄英,等.百草枯建立肺纤维化模型的实验研究[J].空军总医院学报. 2003; 19 (4): 201-202.
54.陆思静,刘又宁,王化洲.丹参对博莱霉素所致大鼠肺纤维化保护作用的研究[J].中国临床药理学与治疗学. 2005; 10(5): 514-517.
55.董静,罗桂林,苗维纳.丹参对实验性肺纤维化小鼠病理变化和核因子-κB表达的影响[J].中国药理学通报. 2003; 19(12): 1428-1431.
56.李学军,崔社怀.三七总苷抗肺纤维化的实验研究[J].药物研究. 2004; 13 (4): 34-35.
57.柴文戍,于镜泊,李永春.当归对肺纤维化大鼠肺形态学及胶原的影响[J].中国全科医学. 2004; 7 (8): 531-533.
58.叶燕青,徐启勇,杨亦斌.当归注射液对大鼠肺纤维化胶原蛋白含量的影响[J].医学新知杂志. 2004; 14 (4): 235-236.
59.赵俭,戴红,张一杰.川芎嗪对博莱霉素所致大鼠肺纤维化的保护作用研究[J].解放军医学杂志. 2005; 30 (5): 455-456.
60.侯杰,蔡后荣,戴令娟.丹参、川芎联合泼尼松治疗特发性肺纤维化的疗效观察[J].实用老年医学. 2001;04,15(2):99-101.
61.陈建,何冰,刘新民,等.银杏叶制剂治疗肺间质纤维化的实验研究[J].中国中西医结合杂志. 2000; 20 (6):441-443..
62.Krishna G, Liu K, Shigemitsu H, et al. PG490-88, a derivative oftriptolide, blocks bleomycin -induced lung fibrosis [J]. Am J Pathol, 2001, l58 (3): 997-100.
63.陈永凤,席景砖,高重阳,等.汉防己甲素对肺纤维化大鼠肺组织钙-钙调素系统的影响[J].新乡医学院学报. 2003; 20 (2): 83-85.
64.张捷,安继红,张伟.刺五加对肺纤维化BALF中IL-6抑制作用的研究[J].中国免疫学杂志. 1995; 11 (5): 300.
65.刘巨源,陈永凤,郭萍,等.黄芪丹参甘草等中药对大鼠肺纤维化的影响[J].新乡医学院学报. 1999; 16 (4): 292-293.
66.张炜,毕小利,马文欢·生地对特发性肺间质纤维化基质重建调控作用的实验研究[J]·中国中医基础医学杂志. 2001;7(6):34-35.
67.宋建平,楚瑞芬,刘方洲,等.栝蒌薤白汤对肺纤维化大鼠支气管肺泡灌洗液中层粘连蛋白、Ⅲ型前胶原含量的影响[J].北京中医药大学学报. 2002; 25 (5): 29-30.
68.周淼.益阴活血汤对大鼠肺纤维化作用的实验研究[J].河南中医学院学报. 2004; 19 (110): 27-28.
69.周亚滨,姚凤祯,刘晓滨,等.肺纤康对平阳霉素所致肺间质纤维化小鼠免疫功能的影响[J].中国中医药科技. 1995; 2 (6): 30.
70.欧阳修河,韩荣庆,张天嵩,等.补气通肺饮对大鼠肺纤维化模型的作用[J].中药新药与临床药理. 1999; 10 (2): 93.
71.宋建平,李瑞琴,李伟,等.乌蛇散对肺纤维化模型作用机理研究[J].中医药学刊. 2001; 19 (5): 515-517.
72.龚婕宁,杨进,周坤福.养肺活血汤防治实验性肺纤维化的研究〔J〕.中国中医基础医学杂志. 2001; 7(6):31.
73.江瑛,祁鑫,李长天,等.消风除湿胶囊对实验性早期肺纤维化基质蛋白的影响〔J〕.甘肃中医. 2001; (2):57.
74.徐杰,刘兴奎.血府逐瘀汤防治平阳霉素引起肺纤维化的实验研究. [J].中医药信息. 2000; (1):49.
75.宋建平,李瑞琴,刘方州,等.复方丹参片、生脉饮、麦门冬汤及肾气丸对平阳霉素所致肺纤维化模型大鼠的影响〔J〕.中医杂志. 2002; 43(2):142.
76.王小平,李晓光,甘丽虹,等.中医治疗肺间质纤维化22例[J].北京中医药大学学报. 2001;24(1):77.
77.赵兰才,武维屏.肺间质纤维化[J].河南中医. 2001; 21(2)50-51.
78.金鸿斌,何春蛾.中药治疗肺间质纤维化[J].河南中医. 2001;21(2):50-51.
79.刘伟.弥漫性肺间质纤维化辨治心得.吉林中医药. 2003; 23(4):4.
80.孔祥文.特发性肺纤维化的中医治疗.现代中西医结合杂志. 2003; 12(1):67-68.
81.邱志楠,潘俊辉,喻清和,等.桃莪丹汤为主治疗特发性肺间质纤维化68例临床观察[J].中国中医药科技. 2002; 9(3):174-175.
82.杨效华,张晓梅,孙海燕,等.肺间质纤维化的中医药治疗[J].中国临床医生. 2002; 30 (6):58-59.
83.陈献亮.虫草汤配合激素治疗特发性肺间质纤维化21例[J].陕西中医. 2002; 23(10):877.
84.刘建博,刘小虹,吴秀美.肺康颗粒治疗弥漫性肺间质纤维化临床观察[J].中国中医急症. 2001; 10(2):77-78.
85.侯杰,戴令娟,母国华.中药丹参、川芎联合强的松治疗特发性肺纤维化的临床疗效[J].医师进修杂志. 2001; 24(1):17-18.
86.辛洪涛,周晓辉,柳澄,等.益气活血法治疗肺间质纤维化临床研究[J].山东医药. 2001; 41(24):9-11.
87.辛洪涛,刘庆华,张欣,等.芪丹颗粒剂治疗肺间质纤维化的临床研究.山东医药,2002; 42(19):20-21.
88.壮健.中医药防治肺间质纤维化的实验研究进展.中医研究. 2005;18(9):58.
2.Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med,2001;110:278-282.
3.Geiser T. Idiopathic pulmonary fibrosis-a disorder of alveolar wound repair? Swiss Med Weekly,2003;133:405-411.
4.柴文戍,李永春等.博莱霉素致肺纤维化大鼠形态学变化的实验研究.中国实验动物学报. 2003;11(2):80.
5.侯显明,于润江.间质性肺病学.第一版.北京:人民卫生出版社. 2003: 222.
6.牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志.2006;26(12):928.
7. Margett s PJ,Bonniaud P,Liu L,et al. Transient overexpression of TGF-beta1 induces epit helial mesenchymal transition in the rodent peritoneum. J Am Soc Nep hrol, 2005;16(2):425-436.
8.邵长周,陈小东,蔡映云.细胞因子在肺纤维化形成中的作用及对治疗方法的启迪.实用心脑肺血管病杂志.2001;9(2):116.
9.Hasegaua M,Sato S,Takehara K,Augmented production chemokines( monocyte chemotatic protein-1, CP-1 ),macrophage inflammatory protein-1alpha (MIP-αand MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-αmay be involved in the development of pullmonary fibrosis.Clin Exp Immunol.1999;117(1):159-165.
10.Standiford TJ, Rolfe MW, KunkelSL, etal. Macrophage inflammatory protein-1αexpression in interstitial lung disease. J Immunol. 1993;151:2852-2863.
11.崔晓丽.培土生金法在呼吸系统疾病中的应用.中医药临床杂志,2005;17(6): 532.
12.赵洪文,彭璐,吕长俊,等.肺纤维化大鼠BALF中细胞成份与肺组织病理的动态研究[J].中国医科大学学报.1997;26(5):463.
13.Kumar RK. Morphological methods for assessment of fibrosis. Methods Mol Med. 2005; 117:179-188.
14.Szapiel SV,et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse[J]. Am Rev Respir Dis. 1979;120(4):893-899.
15.Snider GL,Hayes JA. Korthy AL.Chronic interstitial pulmonary fibrosis produced in hamsters endotracheal bleomyein: pathology and stereology[J]. Am Rev Respir Dis.1978;117(6):1009-1108.
16.刘介眉,严庆汉,路英杰,等.染液的配制和染色方法[M].病理组织染色的理论方法和应用.北京人民卫生出版社.1983;22:36-38.
17.戴令娟,候杰,蔡后荣,等.肺纤维化动物模型肺组织形态定量分析[J].南京铁道医学院学报.1996;15(1):24-27.
18.金洪,田英麟,姚汉德,等.汉防己甲素阻断平阳霉素所致肺间质纤维化的实验研究〔J〕中华结核和呼吸杂志.1991,14(6):359.
19.夏宇.肺纤维化动物模型建立及评价的研究进展.新疆医科大学学报.2005;28 (6): 510–511.
20.苗维纳,等.丹参对实验性肺纤维化小鼠病理变化和转化生长因子-β表达的影响[J].中药药理与临床.2003;19(5):24.
21.魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏系数和肺胶原含量的变化[J].工业卫生与职业病.2001;27 (6):351-353.
22.李才,张一宁,牛俊奇,等.器官纤维化基础与临床[M].北京:人民卫生出版社. 2003:188.
23.南京建成生物工程研究所.HYP试剂盒使用说明.
24.Nagao T, Nagai S, Hiramoto Y, et al. Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia[J]. Respiration,2002;69(5):413.
25.Donald N. Cook, David M. Brass, et al. A Matrix for New Ideas in Pulmonary Fibrosis[J].Am J Respir Cell Mol Bio1,2002;27:122.
26.White E S, Lazar M H, Thannickal V J. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis[J].JPathol, 2003;201(3):343.
27.Piguet P F. Inflammation in idiopathic pulmonary fibrosis[J].Am JRespir Crit Care Med,2003;167(7):1037.
28.罗慰慈.现代呼吸病学〔M}.北京:人民卫生出版社.1997: 119.
29.徐峥嵘.细胞因子及其特异性抑制剂与肺纤维化的治疗[J].中国公共卫生.2005;21(6): 750-753.
30.Brent E Van Hoozen,Katharine L Grimmer,Gregory P Marelich,etal. Early phase collagen synthesis in lungs of rats exposed to bleomycin [J].Gregory P Marelich,et in Toxicology.2000;147(1):1-13.
31.S N Iyer,G Gurujeyalakshmi, S N Giri. Effect of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis[J].The Journal of Pharmacology and Experimental Therapeutics.1999; 289(1):211-218.
32.魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏器系数和肺胶原含量的变化[J].工业卫生与职业病. 2001;27(6):351-353.
33.雷丰峰,等.转化生长因子与肺纤维化[J].新医学.2003;34(11):715.
34高丽,等.细胞因子与肺间质纤维化相关研究进展.内蒙古医学院学报.2006;12 (28): 36-37.
35.李学军,崔社怀.肺纤维化大鼠血浆MCP-1α、MCP-1水平动态变化的观察.解放军医学杂志.2001;26(10):745.
36.李学军,崔社怀.三七总苷抗肺纤维化的实验研究[J].药物研究, 2004, 13 (4): 34-35.
37.辛洪涛,刘庆华,张欣,等.芪丹颗粒剂治疗肺间质纤维化的临床研究.山东医药,2002; 42(19):20-21.
38.武汉博士德生物工程有限公司.即用型SADC免疫组化染色试剂盒使用说明书,2006.
39.刘芳,徐启勇,叶燕青.撷沙坦对肺纤维化模型的干预作用及其对肝细胞生长因子表达的影响[J].中华结核和呼吸杂志.2002;8(7):479-483.
40.黄晓红.MCP-1及其在疾病发生中的作用.国外医学呼吸系统分册.1995;15(4):170-172.
41.魏路清,董彦.肺纤维化发病机制及治疗策略的新观念.国外医学呼吸系统分册.2003;23,(1):38-41
42.Meltzer MS,et al. Cancer Rr,,1977;37:721-725.
43.Yoshimura T,et al.J Exp Med.1989;169:1449-1459.
44.Yashimura T,et al.J Immuno1,1989;142:1956-1962.
45.黄晓红.MCP-1及其在疾病发病中的作用.国外医学呼吸系统分册.1995;15(4):170.
46.Zhang K, Gharaee-Kermani M, Jones ML, etal. Lung monocyte chemoattractant protein -1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol, 1994 ; 153:4733.
47.Snga M,Iyonaga K,Ichiyasn H,et al. Clinical significance of MCP-1 levels in BALF and serum in patients withinterstitil lung diseases. Eur Respir J,1999;14:376.
48.曾钧,宋烈昌,金行中等.地塞米松对肺纤维化大鼠肺单一核细胞趋化蛋白-1基因表达的影响.中国药理学通报.2001;17(l):73-5.
49.Altman LC,et al.J Immuno1.1973;110:801-810.
50.张志琴,呼海燕,司军强. TGF-β在肺纤维化中的作用.农垦医学,2002,24(6):434-435.
51.董翔林,马少林.转化生长因子β在纤维化疾病中的研究与应用.中国临床康复,2004;8(35):8050.
52.崔勇丽等,肺纤维化与细胞因子.国外医学卫生学分册,2002;29(6):325.
53. CokerRK, et al. [J]. Thorax, 2001;56(7):549-556.
54.邵长周等.细胞因子在肺纤维化形成中的作用及对治疗方法的启迪.实用心脑肺血管病杂志,2001;9(2):114.
55.Broeklmann TJ,Limper AH,Colby TV,et al. Transforming growth factorβ1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Prc Natl AcadSci USA,1991;88:6642.
56.Gurujeyalakshmi G,Hollinger MA,Giri SN,et a1. Regulation of transforming growth factor mRNA expression by taurin and niacin in the bleomycin Hamster model of lung fibrosis[J].Am J Repir Cell Mol Bio1,1998;18:33.
57.宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重塑及生长因子的研究[J].中华结核和呼吸杂志,2001;24:283-287.
58.Brass DM,Hoyle GW,Poovey HG,et al. Reduced tumor necrosis factor-alpha and transforming growth factor-betal expression in the lungs of inbred mice that failto develop fibroproliferative lesionsc onsequentt o asbestose xposure[J}.Am J Pathol,1999;154 (3):853-862.
59.李江,武芳,黄茂,等.川芎秦注射液对博莱霉素致肺纤维化大鼠转化生长因子干预作用的研究.时针国医国药,2007;18(6):1289.
60.Coker RK,Eur Respir J,Laurent GJ. Pulmonary fibrosis: cytokines in the balance[J].1998;11:1218-1221.
61.张必萌,等.转化生长因子的生物学效应与纤维化疾病的研究.现代康复.2001; 5 (1) 76-77.
62.Roberts AB, Piek E, Bottinger EP, et al. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? [J].Chest 2001 ; player120 (1supple):43s-47s.
63.Vaillant P, Menard 0, Vignaud JM, The role of cyt.okines in human lung fibrosis[J).Monaldi Arch Chest Dis,1996;51(2):145-152.
64.Sheppard D.Pulmonary fibrosis:a cellular overreaetion or a failure of communication?[J].Clin Invest,2001;107 (12):1501-1502.
65.Khalil S. Regulation of Alveolar Macrophage Transforming Growth Factor-βSecretion by Corticosteroids in Bleompcin-induced Pulmonary inflammation in the Rat[J].J Glin Invest, 1993; 92(4):1812-1818.
66.陈金亮,赵燕峰.肺痿证治渊源探讨[J].陕西中医.2001;(4):220.
67.王永炎,晁恩祥.今日中医内科(中卷)[M].北京:人民卫生出版社,2000:320- 322.
68.侯杰.肺系慢性疾病[M].南京:江苏科技出版社,1984:353.
69.智屹惠.曹世宏教授论治肺间质纤维化[J].南京中医药大学学报(自然科学版) .2001; 17 (3):185-186.
70.张炜,毕小利,马文欢.生地对特发性肺间质纤维化基质重建调控作用的实验研究[J].中国中医基础医学杂志. 2001; 7(6): 34-36.
71.杨和春.浅谈肺系疾病的上盛下虚证治[J].湖北中医杂志.1989;11(5):33-34.
72.宋建平.《金匮要略》所论短气与特发性肺纤维化[J].南京中医药大学学报. 1998; 14 (6): 326-327.
73.张天蒿,马君,韩镭.赵子贤辨治特发性肺间质纤维化经验.浙江中医杂志. 1998; 33(3):102.
74.龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点.浙江中医杂志. 2001; (4) : 139.
75.王海彤,武维屏.中医药治疗弥漫性肺间质纤维化信息讨论.中国中医药信息杂志.1996; 3(7):25.
76.朱玉龙,徐卫方.中医对“肺间质纤维化”的认识.河南中医. 2005;25(12):37.
77.要全保.慢性阻塞性肺病从脾论治初探.中医函授通讯.1999;18(5):15.
78.危北海.有关脾胃学说的理论探讨及临床诊治经验.中医药学刊. 2006; 24 (7): 1191.
79.刘洁文,齐淑玲.血瘀证实质和活血化淤药物作用机理的研究.中医药通报.2003;2(1):4.
80.Ortiz La,lasky J,Hamilton RF,et al.Expressinn of TNF and necessity of TNF - receptors in bleomycin-induced lung injury in mice. Exp Lung Res,1998,24 (6):721-743.
81.Uubaybo,BA. Role of Tumor necrosis factor-in regulating fibrotic lung replair Res. Commun. Mol. Pathol. Pharmacol,1998,l0(1):69.
82.侯杰.肺系慢性疾病[M].南京:江苏科技出版社,1984:353.
83.崔晓丽.培土生金法在呼吸系统疾病中的应用.中医药临床杂志.2005;17(6):532.
84.汪绮石.汪绮石脾胃学术思想探析.中华医史杂志.2002;32(1):39.
85.沈湘妹.培土生金法治疗小儿间质性肺炎.湖北中医杂志.2000;22(11):29.
86.张向前,刘晖.《金匮要略》非脾之疾从脾论治浅探.中国民间疗法.2005;13(12):5.
87.沈映君.中药药理学.第一版.北京:人民卫生出版社.2000:880-881.
88.焦红军.党参的药理作用及其临床应用.药物与临床. 2005;25(4):92.
89.李秋怡,等.川芎的化学成分及药理研究进展.时珍国医国药.2006;17(7):1299.
90.王良兴.川芎嗪对组胺和乙酰胆碱所致豚鼠气管条收缩作用的影响[J].温州医学院学报.1995;25(3):158.
91.李鲁扬,唐占府,孔令钧.复方丹参注射液对冠心病患者血小板活化率的影响[J].山东中医杂志.2001;20(4):20-20.
92.姚富和,张义善,黄麦华,等.复方丹参滴丸治疗稳定型心绞痛50例[J].山东中医杂志.2002;21(3):147-147.
93.孙艳芳,吕晓,韩广明,等.复方丹参注射液治疗糖尿病多发性末梢神经病变34例[J].山东中医杂志.2002;21(8):472-472.
94.王莉,赵长云,赵国瑞,等.复方丹参注射液加黄芪注射液治疗冠心病58例疗效观察[J].中国中医药科技.2002;9(4):252-252.
95.殷静先.白术药理研究进展.时珍国医国药.2000;11(6):572.
96.中华人民共和国药政管理局.现代实用本草.第1版[M].北京:人民卫生出版社.1997∶248.
97.缪竞诚,等.梭甲基获荃多糖对淋巴细胞产生细胞因子的促诱生作用.中成药.1999; 21(12):639。
98.吕苏成,等.茯苓多糖对正常及荷瘤小鼠免疫功能的影响.第一军医大学学报.1990;10(3):267.
99.严晓红,欧阳静萍,涂淑玲,等.当归对氧化低密度脂蛋白所致血管内皮细胞损伤的保护作用[J].湖北医科大学学报.1999;20(3):181-183.
100.夏泉,等.当归的药理作用研究进展.时针国医国药.2004;15(3):3-4.
101.王访,苏耀海.甘草的药理作用及临床应用.时珍国医国药.2002;13(5):303-304.
1.Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement [J] . Am J Respir Crit Care Med, 2000, 161(Pt 1): 646-664.
2.李戎,问智勇,李文军,等.肺纤维化发生与防治机制的重要因素—细胞因子作用机制研究.中国中医药.2004; 6: 23.
3.Sullivan DE, Ferris M,Pociask D, et alTumor necrosis factor-ninduces transforming growth factor-β1 expression in lungfibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol, 2005. 32:342-349.
4.李才,张一宁,牛俊奇,等.器官纤维化—基础与临床.第1版.北京:人民卫生出版社,2003.
5.Huaux F, Liu T, MeGacry B, et al. Dual roles of IL - 4 in lung injury and fbrosis. Immunol ,2003. 170:2083 - 2092.
6.Bresser P, Jansen HM, Weller FR, et al. T-ceB activation in the lungs of patiens with systemic sclerosis and its relation with pulmonary fibrosis. Cheat, 2001, 120:66-68.
7.Huaux F, Louahed J, Hudspith B, et al. Role of interleukin - 10 in the lung response to silica in mice. Am J Respir Cell Mol Bi-o1, 1998 , 18:51- 59.
8.Barbadn V, Xing Z, Delos M, et al. Pul-monery overexpression of IL- 10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol , 2005,288:L841- L848.
9.Brunetti G, Delmastro M, Fonte R, et al. Immunocytological and mineralogical study of bronchoalveolar lavage in a group of subjects exposed to asbestos. G Ital Med Lav Ergon, 2003, 25;152 - l60.
10.Sakamoto H, Zhao LH, Jain F, et al. IL-12p40 mice treated with intratracheal bleomycin exhibit decreased pulmonary inflam-oration and increased fibrosis. Exp Mol Pathol , 2002, 72:1- 9.
11.Barbuleacu K, Backer C, Schlaak JF, et al. IL-12 and IL-18 differentially regulate the tranacriptional activity of the human IFN - gamma promoter in primary CD4+Tlymphocytea. J Immunol, 1998, l60 : 3627 - 3642.
12.李永春,何冰,陈建,等.核因子κВ在大鼠肺纤维化中的活性和表达及红霉素治疗对它的影响.北京医科大学学报.2000; 32:14-17.
13.李学军,崔社怀.三七总皂甙对大鼠肺纤维化过程中血浆MIP-1α、MCP-1含量的影响.第三军医大学学报.2003;25(6)522-524.
14.Standiford TJ,Rolfe MW,Kunkel SL,et al.Macrophage inflammatory protein -1αexpression in interstitial lung disease. J Immunol.1993,151: 2852 ~2863.
15.Zhang K, Kermani MG, Jones ML, et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin induced pulmonary fibrosis.J Immunol.1994,153:4733 ~4741.
16.Sheppard D. Pulmonary fibrosis ; a cellular overreaction or a failure of communication? J Glin Invest, 2001,.107:1501-1502.
17.Bingisser R, Stey C, Welter M, et al. Appotosis in human alveolar maemphaRea is induced by endotoxin and is modulated by cylokines. Am J Respir Cell Mol Biol, 1996,15: 64-70.
18.Willis BC, Liebler JM, Luby-Phelps K, etal. Induction of epithelial- mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am J Pathol ,2005 , 166: 1321- 1332.
19.Silvers MR, Sempowski GD, Phipps RP. Expression of TGF-beta isoforms by Thy-1+and Thy-1-pulmonary Gbrohlaw subsets; evidence for TGF- data as a regulator of IL-1-dependent stimulation of IL-6. Lymphokine Cytokine Res, 1994, 13;227.
20.吴晓梅,王欣燕,陈复辉.两种细胞因了与特发性肺纤维化的关系.中国危重病急救医.2003; 6 : 363.
21.娄克俭.肺纤维化发病机制的研究进展.临床医学.2005;8(4):33
22.曹名波.基质金属蛋白酶及其抑制物与肝纤维化.国外医学消化系疾病分册. 2005; 25:114-117.
23.马万里,李元桂,辛建保.基质金属蛋白酶及金属蛋白酶组织抑制剂在肺纤维化中的变化.华中科技大学学报(医学版).2002;31; 527-533.
24.Gurujeyalashmi G,Giri SN. Molocular mechanism of antifibrotic effect of inter-ferongamma in belomycin-mouse model of lung fibrosis: down regulation of TGF-beta and procollagen I and 11I gene expression. Exp Lung Res, 1995. 21: 791-809
25.Ziesche H, Hotbauer E, W ittmann K,et al. Apreliminary study of long term treatment with interferon gamma-1b and lowdose prxlnisolone in patients with idiopathic pulmonary Fbrosis. Nengl 7 Med, 1999, 341: 1264-1269
26.Millar A. Anti-cytokine therapy in fibrossing alveoitis: where are we now? Respir ReRes, 2000, 1: 3-5.
27.erohand-Adam S, Plentier L, Bernuau D, et al. Kerntinocyte growth factor expression by fibroblasta in pulmonary fibrosis; poor response to interleukin-1 ? Am 1 Respir Cell Mol Biol, 2005, 32; 470-477.
28.Baraxzone C, Donati VR, Rochat AF, et al.Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol ,1999, 154:1479-1487.
29.Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to acid instiVation in rata. Am1 Respir Cell Mol Biol, 1996,15:433.
30.Viget NB, Guery BP, Ader F, et al. Keretinacyte growth factor protects against pseudomonas aenrginose2 induced lung injury. Am 1 Physiol Lung Cell Mol Physiol, 2000, 279: L1199-L1209.
31.陈刚,吴允孚,周彩存.角质细胞生长因子和肝细胞生长因子在肺感染及损伤修复中的作用,医学综述.2005; 11: 936– 938
32.GulsvikA, KjelsbergA, Bergmann, et al. High 2 dose intravenous methyl prednisolone pulse therapy asinitial treatment incryptogenic fibrosis singal veolitis: apilotstudy[J].Respiration, 1986, 50: 252.
33.Douglas W, Ryu J H , wensen SJ , et al . Colchicine versus prednisone in the treatment of idiopat hic pulmonary fibrosis: a randomized prospective study. A m J Respi r Crit Care Med , 1998 , 158 (1): 220-226.
34.Molteni A, Moulder J E, cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensinⅡtype
35.Desaki M ,Okazaki H ,Sunazuka T ,et al ,Molecular mechanism of anti2inflammatory action of eryt hromycin in human bronchia epit helial cells : possible role in the signaling pat hway t hat regulates nuclear factor2kappaB activation. Antimi crob Agents Chemother,2004,48(5):1581-1585.
36.Li Y, Azuma A , Usuki J , et al . EM703 improves bleomycin induced pulmonary fibrosis in mice by t he inhibition of TGF-beta signaling in lung fibrosis. Respir Res, 2006, 7 (1) :18-20.
37.Behr J, Maier K, Degenkolb B, et al . Antioxidative and clinical effects of high2dose N2acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med, 1997, 156 (6): 1897-1901.
38.Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis wit h a new antifibrotic agent, pirfenidone: results of a prospective, openabel PhaseⅡstudy. Am J Respir Crit, Care Med, 1999, 159 (4 pt 1): 1061-1064.
39.Azuma A, Expectation of new treatments for idiopathic interstitial pneumonias. Nippon Ronen Igakkai Zasshi, 2005, 42 (1): 27-30.
40.Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long term treatment wit h interferon Gamma21b and low dose prednisolone in patients wit h idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2004, 31 (6): 679-686.
41.Wang Q, Wang Y, Hyde DM , et al . Reduction of bleomycin induced lung fibrosis by transforming growt h factor beta soluble receptor in hamsters. Thorax, 1999, 54 (9): 805-812.
42.Kolb M , Margetts PJ , Galt T , et al . Transient t ransgene expression of decorin in the lung reduces t he fibrotic response to bleomycin. Am J Repir Crit Care Med, 2001, 163 (3 pt 1): 770-777.
43.李伟杰,齐景宪.肺纤维化治疗新进展.医师进修杂志.1999; 2(22): 52-55
44.牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展.国际呼吸杂志.2006; 12,(26): 928-931.
45.智屹惠.曹世宏教授论治肺间质纤维化[J].南京中医药大学学报(自然科学版) .2001; 17 (3):185-186.
46.张炜,毕小利,马文欢.生地对特发性肺间质纤维化基质重建调控作用的实验研究[J].中国中医基础医学杂志. 2001; 7(6): 34-36.
47.宋建平.《金匮要略》所论短气与特发性肺纤维化[J].南京中医药大学学报. 1998; 14 (6): 326-327.
48.张天蒿,马君,韩镭.赵子贤辨治特发性肺间质纤维化经验.浙江中医杂志. 1998; 33(3):102.
49.龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点.浙江中医杂志. 2001; (4) : 139.
50.孟磊,陈军,高彩霞.活血祛瘀法为主治疗特发性肺纤维化[J].河南中医. 2002; 22(4): 58-59.
51.王健.肺纤维化的实验研究及HRCT[J].国外医学·临床放射学分册. 1998; (2): 74-77.
52.Zia S,Hyde D M, Giri S N.Development of a bleomycin hamster model of subchronic lung fibrosis[J]. Pathology,1992,24:155.
53.高燕,雍政,黄英,等.百草枯建立肺纤维化模型的实验研究[J].空军总医院学报. 2003; 19 (4): 201-202.
54.陆思静,刘又宁,王化洲.丹参对博莱霉素所致大鼠肺纤维化保护作用的研究[J].中国临床药理学与治疗学. 2005; 10(5): 514-517.
55.董静,罗桂林,苗维纳.丹参对实验性肺纤维化小鼠病理变化和核因子-κB表达的影响[J].中国药理学通报. 2003; 19(12): 1428-1431.
56.李学军,崔社怀.三七总苷抗肺纤维化的实验研究[J].药物研究. 2004; 13 (4): 34-35.
57.柴文戍,于镜泊,李永春.当归对肺纤维化大鼠肺形态学及胶原的影响[J].中国全科医学. 2004; 7 (8): 531-533.
58.叶燕青,徐启勇,杨亦斌.当归注射液对大鼠肺纤维化胶原蛋白含量的影响[J].医学新知杂志. 2004; 14 (4): 235-236.
59.赵俭,戴红,张一杰.川芎嗪对博莱霉素所致大鼠肺纤维化的保护作用研究[J].解放军医学杂志. 2005; 30 (5): 455-456.
60.侯杰,蔡后荣,戴令娟.丹参、川芎联合泼尼松治疗特发性肺纤维化的疗效观察[J].实用老年医学. 2001;04,15(2):99-101.
61.陈建,何冰,刘新民,等.银杏叶制剂治疗肺间质纤维化的实验研究[J].中国中西医结合杂志. 2000; 20 (6):441-443..
62.Krishna G, Liu K, Shigemitsu H, et al. PG490-88, a derivative oftriptolide, blocks bleomycin -induced lung fibrosis [J]. Am J Pathol, 2001, l58 (3): 997-100.
63.陈永凤,席景砖,高重阳,等.汉防己甲素对肺纤维化大鼠肺组织钙-钙调素系统的影响[J].新乡医学院学报. 2003; 20 (2): 83-85.
64.张捷,安继红,张伟.刺五加对肺纤维化BALF中IL-6抑制作用的研究[J].中国免疫学杂志. 1995; 11 (5): 300.
65.刘巨源,陈永凤,郭萍,等.黄芪丹参甘草等中药对大鼠肺纤维化的影响[J].新乡医学院学报. 1999; 16 (4): 292-293.
66.张炜,毕小利,马文欢·生地对特发性肺间质纤维化基质重建调控作用的实验研究[J]·中国中医基础医学杂志. 2001;7(6):34-35.
67.宋建平,楚瑞芬,刘方洲,等.栝蒌薤白汤对肺纤维化大鼠支气管肺泡灌洗液中层粘连蛋白、Ⅲ型前胶原含量的影响[J].北京中医药大学学报. 2002; 25 (5): 29-30.
68.周淼.益阴活血汤对大鼠肺纤维化作用的实验研究[J].河南中医学院学报. 2004; 19 (110): 27-28.
69.周亚滨,姚凤祯,刘晓滨,等.肺纤康对平阳霉素所致肺间质纤维化小鼠免疫功能的影响[J].中国中医药科技. 1995; 2 (6): 30.
70.欧阳修河,韩荣庆,张天嵩,等.补气通肺饮对大鼠肺纤维化模型的作用[J].中药新药与临床药理. 1999; 10 (2): 93.
71.宋建平,李瑞琴,李伟,等.乌蛇散对肺纤维化模型作用机理研究[J].中医药学刊. 2001; 19 (5): 515-517.
72.龚婕宁,杨进,周坤福.养肺活血汤防治实验性肺纤维化的研究〔J〕.中国中医基础医学杂志. 2001; 7(6):31.
73.江瑛,祁鑫,李长天,等.消风除湿胶囊对实验性早期肺纤维化基质蛋白的影响〔J〕.甘肃中医. 2001; (2):57.
74.徐杰,刘兴奎.血府逐瘀汤防治平阳霉素引起肺纤维化的实验研究. [J].中医药信息. 2000; (1):49.
75.宋建平,李瑞琴,刘方州,等.复方丹参片、生脉饮、麦门冬汤及肾气丸对平阳霉素所致肺纤维化模型大鼠的影响〔J〕.中医杂志. 2002; 43(2):142.
76.王小平,李晓光,甘丽虹,等.中医治疗肺间质纤维化22例[J].北京中医药大学学报. 2001;24(1):77.
77.赵兰才,武维屏.肺间质纤维化[J].河南中医. 2001; 21(2)50-51.
78.金鸿斌,何春蛾.中药治疗肺间质纤维化[J].河南中医. 2001;21(2):50-51.
79.刘伟.弥漫性肺间质纤维化辨治心得.吉林中医药. 2003; 23(4):4.
80.孔祥文.特发性肺纤维化的中医治疗.现代中西医结合杂志. 2003; 12(1):67-68.
81.邱志楠,潘俊辉,喻清和,等.桃莪丹汤为主治疗特发性肺间质纤维化68例临床观察[J].中国中医药科技. 2002; 9(3):174-175.
82.杨效华,张晓梅,孙海燕,等.肺间质纤维化的中医药治疗[J].中国临床医生. 2002; 30 (6):58-59.
83.陈献亮.虫草汤配合激素治疗特发性肺间质纤维化21例[J].陕西中医. 2002; 23(10):877.
84.刘建博,刘小虹,吴秀美.肺康颗粒治疗弥漫性肺间质纤维化临床观察[J].中国中医急症. 2001; 10(2):77-78.
85.侯杰,戴令娟,母国华.中药丹参、川芎联合强的松治疗特发性肺纤维化的临床疗效[J].医师进修杂志. 2001; 24(1):17-18.
86.辛洪涛,周晓辉,柳澄,等.益气活血法治疗肺间质纤维化临床研究[J].山东医药. 2001; 41(24):9-11.
87.辛洪涛,刘庆华,张欣,等.芪丹颗粒剂治疗肺间质纤维化的临床研究.山东医药,2002; 42(19):20-21.
88.壮健.中医药防治肺间质纤维化的实验研究进展.中医研究. 2005;18(9):58.